Nov. 9 Quick Takes: Arbor’s $215M round attracts Temasek, Ally Bridge, TCG

Temasek, Ally Bridge Group and TCG Crossover led a crossover-laden $215 million series B round for Arbor Biotechnologies Inc., bringing the total raised by the Cambridge, Mass. gene editing company to more than $300 million. Fellow new investors Arrowmark Partners, Deep Track Capital, Great Point Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, Ono Venture Investment, Piper Heartland Healthcare Capital, Ridgeback Capital Investments, Section 32, Citadel’s Surveyor Capital, T. Rowe Price Associates, Tao Capital Partners, Tekla Capital Management, Woodline Partners also participated along with strategic partner Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). Existing investor Arch Venture Partners also participated in the round for Arbor, which Feng Zhang, David Walt, David Scott and Winston Yan founded in 2016.

Alkermes plc (NASDAQ:ALKS) lost 15% after Janssen Pharmaceutica N.V. partially terminated its two license agreements through which it gained access to NanoCrystal, a nanoparticulate formulation technology. This termination will stop the flow of know-how royalties Janssen paid from the sales of long-acting paliperidone products, such as Invega Sustenna and Invega Trinza. The partial termination becomes effective three months after the date of receipt of the notice. Janssen maintains that it has not utilized the technology licensed under the agreement. Alkermes said that Janssen has previously highlighted use of their technology in INVEGA products, and isn’t aware of any changes that would have altered the use of its IP...